Pivmecillinam plus pivampicillin in urinary tract infections: a randomized, open comparison with co-trimoxazole in hospitalized patients.
The efficacy and tolerance of a fixed-dose combination of 200 mg pivmecillinam and 250 mg pivampicllin was compared with that of co-trimoxazole (800 mg sulphamethoxazole plus 160 mg trimethoprim) in 42 hospital in-patients with complicated urinary tract infections. Patients received a 10-day course of tablets of either agent twice daily. The infecting organisms, which were Enterobacteriaceae (79%) and enterococci (21%), were eradicated in 17(89%) of the 19 patients given co-trimoxazole and in all 23 subjects who received pivmecillinam/pivampicillin. Sixteen (89%) of the 18 symptomatic patients responded clinically to co-trimoxazole. Pivmecillinam/pivampicillin was effective in 19 (95%) of 20 patients with symptomatic infections. There was a fairly good correlation between the bacteriological and clinical responses. No serious side-effects were recorded and all patients completed the prescribed course of treatment.
D000328:Adult; D000368:Aged; D000561:Amdinocillin Pivoxil / Q000627:therapeutic use*; D000667:Ampicillin / Q000031:analogs & derivatives*; D002986:Clinical Trials as Topic; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010397:Penicillanic Acid / Q000627:therapeutic use*; D010917:Pivampicillin / Q000627:therapeutic use*; D011897:Random Allocation; D013420:Sulfamethoxazole / Q000627:therapeutic use*; D014295:Trimethoprim / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014552:Urinary Tract Infections / Q000188:drug therapy*
D004338:Drug Combinations; D010917:Pivampicillin; D000561:Amdinocillin Pivoxil; D000667:Ampicillin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D010397:Penicillanic Acid; D014295:Trimethoprim; D013420:Sulfamethoxazole